Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

1.

A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA.

Masson-Lecomte A, Guy L, Pedron P, Bruyere F, Rouprêt M, Nsabimbona B, Dahan M, Hoffman P, Salomon L, Vordos D, Hoznek A, Le Corvoisier P, Morel P, Abbou C, de la Taille A.

World J Urol. 2013 Apr;31(2):339-43. doi: 10.1007/s00345-012-0841-1. Epub 2012 Apr 15.

PMID:
22527669
[PubMed - indexed for MEDLINE]
2.

Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.

Raddin RS, Walko CM, Whang YE.

Anticancer Drugs. 2011 Mar;22(3):299-302.

PMID:
21360851
[PubMed - indexed for MEDLINE]
3.

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.

BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x.

PMID:
19035858
[PubMed - indexed for MEDLINE]
4.

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.

Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG.

Urology. 1999 May;53(5):898-902; discussion 902-3.

PMID:
10223480
[PubMed - indexed for MEDLINE]
5.

New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.

Garnick MB, Mottet N.

BJU Int. 2012 Aug;110(4):499-504. doi: 10.1111/j.1464-410X.2011.10708.x. Epub 2011 Nov 16.

PMID:
22093775
[PubMed - indexed for MEDLINE]
6.

Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.

Ulmert D, Vickers AJ, Scher HI, Becker C, Iversen P, Frankel D, Jensen JK, Olesen TK, Lilja H.

Clin Chem Lab Med. 2012 Nov;50(11):1993-8.

PMID:
22718641
[PubMed - indexed for MEDLINE]
Free PMC Article
7.
8.

The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.

Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y, Takeda K, Ohashi Y, Tsukamoto T, Naito S, Akaza H.

Jpn J Clin Oncol. 2012 Jun;42(6):477-84. doi: 10.1093/jjco/hys035. Epub 2012 Mar 28.

PMID:
22457321
[PubMed - indexed for MEDLINE]
Free Article
9.
10.

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.

Damber JE, Tammela TL, Iversen P, Abrahamsson PA, Boccon-Gibod L, Olesen TK, van der Meulen E, Persson BE.

Urology. 2012 Jul;80(1):174-80. doi: 10.1016/j.urology.2012.01.092.

PMID:
22748873
[PubMed - indexed for MEDLINE]
11.

[Change of the LHRH analogue in progressive castration-refractory prostate cancer].

Heidenreich A, Porres D, Epplen R, van Erps T, Pfister D.

Urologe A. 2012 Sep;51(9):1282-7. doi: 10.1007/s00120-012-2948-9. German.

PMID:
22733398
[PubMed - indexed for MEDLINE]
12.

Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.

Beer TM, Garzotto M, Eilers KM, Lemmon D, Wersinger EM.

Urology. 2004 Feb;63(2):342-7.

PMID:
14972486
[PubMed - indexed for MEDLINE]
13.

The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.

Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB.

J Urol. 2001 May;165(5):1585-9.

PMID:
11342922
[PubMed - indexed for MEDLINE]
14.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

PMID:
22369348
[PubMed - indexed for MEDLINE]
15.

Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.

Miller N, Smolkin ME, Bissonette E, Theodorescu D.

Cancer. 2005 Jun 15;103(12):2499-506.

PMID:
15852361
[PubMed - indexed for MEDLINE]
Free Article
16.

Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.

Steinberg M.

Clin Ther. 2009;31 Pt 2:2312-31. doi: 10.1016/j.clinthera.2009.11.009. Review.

PMID:
20110043
[PubMed - indexed for MEDLINE]
17.

Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.

Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.

Can J Urol. 2009 Oct;16(5):4806-12.

PMID:
19796455
[PubMed - indexed for MEDLINE]
18.

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE.

J Urol. 2011 Sep;186(3):889-97. doi: 10.1016/j.juro.2011.04.083. Epub 2011 Jul 23.

PMID:
21788033
[PubMed - indexed for MEDLINE]
19.

Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.

Zuckerman JM, Eure G, Malcolm J, Currie L, Given R.

Urology. 2014 Mar;83(3):670-4. doi: 10.1016/j.urology.2013.10.036. Epub 2013 Dec 19.

PMID:
24360065
[PubMed - indexed for MEDLINE]
20.

Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.

Van Poppel H, Klotz L.

Int J Urol. 2012 Jul;19(7):594-601. doi: 10.1111/j.1442-2042.2012.02997.x. Epub 2012 Mar 14. Review.

PMID:
22416801
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk